Drug Transporter (DT) Information

General Information of DT
DT ID DTD0475
Gene Name SLC7A8
Protein Name L-type amino acid transporter 2
Gene ID
23428
UniProt ID
Q9UHI5
TCDB ID
2.A.3.8.20
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 6JMQ_A

Identity: 53.593%

Minimized Score: -1054.292 kcal/mol

Detail: Structure Info

Synonyms LAT2; LPI-PC1; Large neutral amino acids transporter small subunit 2; SLC7A8; Solute carrier family 7 member 8; hLAT2
DT Family Amino Acid-Polyamine-Organocation (APC) Family
L-type Amino Acid Transporter (LAT) Family
Tissue Specificity Strongest expression is observed in kidney andmoderate expression in placenta and brain, followed by liver,prostate, testis, ovary, lymph node, thymus, spleen, skeletalmuscle and heart. Also expressed in fetal liver as well as in theretinal pigment epithelial cell line ARPE-19 and the intestinalepithelial cell line Caco-2.
Function This transporter plays an essential role in the reabsorption of neutral amino acids from the epithelial cells to the bloodstream in the kidney, such as alanine, serine, threonine, cysteine, phenylalanine, tyrosine, leucine, arginine and tryptophan. Acts as an amino acid exchanger. Has higher affinity for L-phenylalanine than LAT1 but lower affinity for glutamine and serine. L-alanine is transported at physiological concentrations. Plays a role in basolateral (re)absorption of neutral amino acids. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the transmembrane.
Disease(s) Dietary shortage [ICD-11: 5B7Z]
Endogenous Substrate(s) Asparagine; Methionine; Cystine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT (VARIDT 1.0)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            6 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Glycine
 Approved Drug Info Dietary shortage 5B7Z [1]
L-alanine
 Approved Drug Info Glioma 2A00.0 [1]
L-phenylalanine
 Approved Drug Info Dietary shortage 5B7Z [2]
L-proline
 Approved Drug Info Dietary shortage 5B7Z [1]
L-tryptophan
 Approved Drug Info Depression 6A8Z [1]
L-tyrosine
 Approved Drug Info Dietary shortage 5B7Z [1]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
L-phenylalanine Approved Drug Info Xenopus oocytes-LAT2 Km = 12.2 microM [2]
References
1 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
2 Quantifying the relative contributions of different solute carriers to aggregate substrate transport. Sci Rep. 2017 Jan 16;7:40628.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.